Risk In Pharmaceutical Packaging
Source: ISPE
Shifting the industry from a compliance culture to a quality culture in pharmaceutical packaging.
In 2010, an examination of 16 FDA consent decrees conducted by Jim Prutow and PRTM researchers (a healthcare consultancy practice) found that one decree had stretched on for 21 years and was still in force, while another had been in force for 17 years and counting. This is not unusual: The majority of pharmaceutical manufacturing consent decrees linger, remaining in force with no official closeout. The cost of these federal decrees to the organizations can run from tens to hundreds of millions of dollars.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more